Renal function among patients who have completed trimodal therapy for bladder cancer declines slightly after 1 year of follow-up but remains stable thereafter for up to 10 years, investigators reported at the Society of Urologic Oncology’s 23rd annual meeting in San Diego, California.
Trimodal therapy is a standard treatment option for selected patients with muscle-invasive bladder cancer, but its long-term effect on renal function had not previously been investigated, according to Linda V. Nguyen, MD, MS, of Massachusetts General Hospital in Boston, and colleagues. Various types of chemotherapy agents, including mitomycin, 5-fluorouracil, and cisplatin, are known to be toxic to the kidneys.
“As many bladder cancer patients are elderly with significant medical comorbidities, data on long-term renal function would aid in selecting the appropriate management,” the authors noted in a study abstract.
Dr Nguyen’s team studied 251 patients undergoing trimodal therapy to evaluate change in renal function over 10 years in patients who have completed the treatment. They collected estimated glomerular filtration rate (eGFR) values at baseline and at years 1, 3, 5, and 10 after the date of bladder cancer diagnosis. Mean eGFR values at these time points were 65.67, 58.43, 55.40, 54.54, and 57.30 mL/min/1.73 m2, respectively.
The investigators used the CKD-EPI creatinine equation to calculate eGFR values.
Nguyen LV, Hunter AE, Shipley AE, et al. Long term renal function outcomes in trimodality therapy for bladder cancer. Presented at: SUO 2022, November 30 to December 2, San Diego, California. Poster 6.